PPARA and primary biliary cholangitis: However, until now, PPAR-α expression has not been evaluated in the mononuclear cells of patients with cholestatic immune-mediated conditions, even though PPAR-α activation via FB is an FDA-approved adjunct therapy for ursodeoxycholic acid-refractory PBC patients.